Unraveling the role of cancer-associated fibroblasts in colorectal cancer

Within the intricate milieu of colorectal cancer(CRC)tissues,cancer-associated fibroblasts(CAFs)act as pivotal orchestrators,wielding considerable influence over tumor progression.This review endeavors to dissect the multifaceted functions of CAFs within the realm of CRC,thereby highlighting their indispensability in fostering CRC malignant microenvironment and indicating the development of CAFs-targeted therapeutic interventions.Through a comprehensive synthesis of current knowledge,this review delineates insights into CAFsmediated modulation of cancer cell proliferation,invasiveness,immune evasion,and neovascularization,elucidating the intricate web of interactions that sustain the pro-tumor metabolism and secretion of multiple factors.Additionally,recognizing the high level of heterogeneity within CAFs is crucial,as they encompass a range of subtypes,including myofibroblastic CAFs,inflammatory CAFs,antigen-presenting CAFs,and vessel-associated CAFs.Innovatively,the symbiotic relationship between CAFs and the intestinal microbiota is explored,shedding light on a novel dimension of CRC pathogenesis.Despite remarkable progress,the orchestrated dynamic functions of CAFs remain incompletely deciphered,underscoring the need for continued research endeavors for therapeutic advancements in CRC management.

塞来昔布联合FOLFOX4方案治疗晚期胃癌的疗效及机制研究

目的探讨塞来昔布联合FOLFOX4方案治疗人晚期胃癌的效果及可能的作用机制。方法选取2015年9月-2017年5月潍坊医学院附属医院消化科就诊的符合条件的经电子胃镜和病理证实为晚期胃癌的患者,共80例。随机分成两组,其中实验组40例,应用塞来昔布联合FOLFOX4化疗方案,对照组40例,应用FOLFOX4化疗方案。根据治疗效果的不同分为完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)。参考WHO实体瘤疗效评价标准评价治疗效果。分别采用逆转录聚合酶链反应(RT-PCR)、免疫组织化学、Western blot检测治疗后胃癌组织中ABCG2、OCT-4、HIF-2α的m RNA及其蛋白表达。结果80例患者经过4周期治疗后,实验组有效率为77.5%,对照组有效率为42.5%,差异有统计学意义(P<0.05),实验组与对照组HIF-2α、ABCG2、OCT-4的m RNA和蛋白相对表达量差异均有统计学意义(P<0.05)。实验组表达减弱。结论塞来昔布联合FOLFOX4治疗晚期胃癌有效率高于FOLFOX4方案,胃癌组织中ABCG2、OCT-4、HIF-2α的m RNA和蛋白表达量降低,其机制可能通过降低HIF-2α-ABCG2和HIF-2α-OCT-4通路的表达影响胃癌的发展和转移,进而影响肿瘤的化疗抵抗、多药耐药。